Arcutis Biotherapeutics (ARQT) Stock Analysis & Winston Score

Arcutis Biotherapeutics is a pharmaceutical company that makes prescription skin treatments. Its products target common but difficult-to-treat conditions like plaque psoriasis, seborrheic dermatitis, and eczema. Its approved drugs include Zoryve (roflumilast), which comes in both a cream and a foam formulation, and are sold to dermatologists and patients across the United States. The company earns money by selling its prescription drugs directly to pharmacies and specialty distributors, who then fill patient prescriptions. Arcutis operates almost entirely in the U.S. market and, with a roughly $3.4 billion market cap, is considered a small-to-mid-sized specialty pharma company. Its 90% gross margin reflects the high pricing power typical of branded dermatology drugs, but its operating margin is barely above zero, meaning it still spends heavily on sales and marketing to grow its relatively new product line. The key risk is whether Arcutis can keep growing Zoryve revenue fast enough to cover those costs before facing generic competition or insurance coverage challenges.